Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.

Epidermal growth factor receptor (EGFR) exists in the nucleus of highly proliferative cells where it functions as a transcription factor. Although EGFR has transactivational activity, it lacks a DNA binding domain and, therefore, may require a DNA binding transcription cofactor for its transcriptional function. Here, we report that EGFR physically interacts with signal transducers and activators of transcription 3 (STAT3) in the nucleus, leading to transcriptional activation of inducible nitric oxide synthase (iNOS). In breast carcinomas, nuclear EGFR positively correlates with iNOS. This study describes a mode of transcriptional control involving cooperated efforts of STAT3 and nuclear EGFR. Our work suggests that the deregulated iNOS/NO pathway may partly contribute to the malignant biology of tumor cells with high levels of nuclear EGFR and STAT3.

[1]  Y. Soini,et al.  Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. S. Gutkind,et al.  Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.

[3]  J. Darnell,et al.  Independent and Cooperative Activation of Chromosomal c-fos Promoter by STAT3* , 2003, The Journal of Biological Chemistry.

[4]  R. Schulte‐Hermann,et al.  A novel mechanism for mitogenic signaling via pro–transforming growth factor α within hepatocyte nuclei , 2002, Hepatology.

[5]  Y. Chan,et al.  Neurotrophin receptor immunostaining in the vestibular nuclei of rats , 2003, Neuroreport.

[6]  Huang Shao,et al.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.

[7]  D. Geller,et al.  Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. M. Green,et al.  Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  T. Hirano,et al.  Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. , 1999, Immunity.

[10]  D. Nathans,et al.  In vitro activation of Stat3 by epidermal growth factor receptor kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Subramaniam,et al.  Differential Nuclear Localization of the IFNGR-1 and IFNGR-2 Subunits of the IFN-γ Receptor Complex Following Activation by IFN-γ , 2000 .

[12]  F. Cianchi,et al.  Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. , 2003, The American journal of pathology.

[13]  T. Grunt,et al.  c-erbB-3 , 2002, The Journal of cell biology.

[14]  P. Subramaniam,et al.  Lipid Microdomains Are Required Sites for the Selective Endocytosis and Nuclear Translocation of IFN-γ, Its Receptor Chain IFN-γ Receptor-1, and the Phosphorylation and Nuclear Translocation of STAT1α1 , 2002, The Journal of Immunology.

[15]  E. Reddy,et al.  Elk-1 proteins are phosphoproteins and activators of mitogen-activated protein kinase. , 1993, Cancer research.

[16]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[17]  M. Hung,et al.  Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors , 2004, Cancer Research.

[18]  M. O’connor,et al.  Induction and activity of nitric oxide synthase in cultured human intestinal epithelial monolayers. , 1996, The American journal of physiology.

[19]  S. Murakami,et al.  Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway , 2002, Oncogene.

[20]  T. Hirano,et al.  A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.

[21]  B. Barre,et al.  Opposite Regulation of Myc and p21 waf1 Transcription by STAT3 Proteins* , 2003, The Journal of Biological Chemistry.

[22]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[23]  P. Maher Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2 , 1996, The Journal of cell biology.

[24]  J. Abbruzzese,et al.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.

[25]  M. Hung,et al.  Systemic tumor suppression by the proapoptotic gene bik. , 2002, Cancer research.

[26]  A. Orucevic,et al.  Role of nitric oxide in tumor progression: Lessons from experimental tumors , 1998, Cancer and Metastasis Reviews.

[27]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[28]  J. Turkson,et al.  Cytoplasmic transport of Stat3 by receptor‐mediated endocytosis , 2002, The EMBO journal.

[29]  P Rhodes,et al.  Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Heinrich,et al.  Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level , 1993, Molecular and cellular biology.

[31]  F. Cianchi,et al.  Cyclooxygenase-2 Activation Mediates the Proangiogenic Effect of Nitric Oxide in Colorectal Cancer , 2004, Clinical Cancer Research.

[32]  P. Coffer,et al.  EGF receptor deletions define a region specifically mediating STAT transcription factor activation. , 1995, Biochemical and biophysical research communications.

[33]  J. Massagué,et al.  OAZ Uses Distinct DNA- and Protein-Binding Zinc Fingers in Separate BMP-Smad and Olf Signaling Pathways , 2000, Cell.

[34]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  G. Rassidakis,et al.  Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  R. Jove,et al.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.

[37]  T. Fitzgerald,et al.  Differential expression of nitric oxide synthases in EGF-responsive mouse neural precursor cells , 1999, Cell and Tissue Research.

[38]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[39]  J. Mouscadet,et al.  The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[40]  L. Magnelli,et al.  Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. , 2002, Biochemical and biophysical research communications.

[41]  M. Hung,et al.  Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. , 2005, Cancer research.

[42]  J. Turkson,et al.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.

[43]  A. Hamburger,et al.  ErbB‐2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells , 1999, International journal of cancer.

[44]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[45]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[46]  E. Qwarnstrom,et al.  IL-1 and its receptor are translocated to the nucleus. , 1990, Journal of immunology.

[47]  A. Bridges,et al.  A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.

[48]  C. Rao,et al.  Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.

[49]  J. Hsuan,et al.  EGF receptors as transcription factors: ridiculous or sublime? , 2001, Nature Cell Biology.

[50]  M. Moran,et al.  Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. , 1990, Science.

[51]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[52]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Barker,et al.  Localization of epidermal growth factor receptor in hepatocyte nuclei , 1991, Hepatology.

[54]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[55]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[56]  K. Yung,et al.  Receptors of Glutamate and Neurotrophin in Vestibular Neuronal Functions , 2003, Journal of Biomedical Science.

[57]  M. Masuda,et al.  Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.

[58]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[59]  Michael Chinkers,et al.  A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. , 1982, The Journal of biological chemistry.

[60]  F. Xy From PTK-STAT signaling to caspase expression and apoptosis induction. , 1999 .

[61]  D. Jans,et al.  Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling? , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[62]  W. Cance,et al.  A decade of tyrosine kinases: from gene discovery to therapeutics. , 2003, Surgical oncology.

[63]  A. Buzaid,et al.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  T. Golde,et al.  γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.

[65]  A. Dowlati,et al.  Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. , 2004, Molecular cancer therapeutics.

[66]  D. Jans,et al.  The cytokine interleukin‐5 (IL‐5) effects cotransport of its receptor subunits to the nucleus in vitro , 1997, FEBS letters.

[67]  M. Hung,et al.  Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[68]  G. Devries,et al.  Localization of neuregulin isoforms and erbB receptors in myelinating glial cells , 2004, Glia.

[69]  A. Shiau,et al.  Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis , 2003, British Journal of Cancer.

[70]  H. Hauser,et al.  Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: The role of NF-κB-repressing factor (NRF) in basal repression of the hiNOS gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  P. Lala,et al.  Animal Model Nitric Oxide Synthase Inhibition by N G -Nitro- L Arginine Methyl Ester Inhibits Tumor-Induced Angiogenesis in Mammary Tumors , 1999 .

[72]  T. Bader,et al.  Nuclear accumulation of interferon gamma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Maher,et al.  Importin β–Mediated Nuclear Import of Fibroblast Growth Factor Receptor , 2001, The Journal of Cell Biology.

[74]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  M. Herlyn,et al.  Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. , 1988, Cancer research.

[76]  M. O’Connor-McCourt,et al.  Predominant intracellular localization of the type I transforming growth factor-beta receptor and increased nuclear accumulation after growth arrest. , 2000, Experimental cell research.

[77]  A. Ullrich,et al.  Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors , 1992, Molecular and cellular biology.

[78]  A. Vannacci,et al.  The MDR phenotype is associated with the expression of COX‐2 and iNOS in a human hepatocellular carcinoma cell line , 2002, Hepatology.

[79]  Frank E. Jones,et al.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.

[80]  J. Olefsky,et al.  Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. , 1987, The Journal of biological chemistry.

[81]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[82]  J. Reichrath,et al.  Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. , 2002, Anticancer research.

[83]  Teresa Reguly,et al.  In or out? The dynamics of Smad nucleocytoplasmic shuttling. , 2003, Trends in cell biology.

[84]  A. Wells,et al.  Signalling shortcuts: cell-surface receptors in the nucleus? , 2002, Nature Reviews Molecular Cell Biology.

[85]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[86]  Bin Liu,et al.  Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy , 2003, Neurobiology of Disease.

[87]  M. Hung,et al.  Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. , 1994, Biochemical and biophysical research communications.

[88]  Carlos Arteaga,et al.  Targeting HER1/EGFR: a molecular approach to cancer therapy. , 2003, Seminars in oncology.

[89]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[90]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[91]  J. Baselga,et al.  Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. , 2001, Seminars in oncology.

[92]  S. Cohen,et al.  Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[93]  P. Farnham,et al.  The identification of E2F1-specific target genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[94]  U. Marti,et al.  Acinar and cellular distribution and mRNA expression of the epidermal growth factor receptor are changed during liver regeneration. , 1995, Journal of hepatology.

[95]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[96]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.